

State Demonstrations Group

October 5, 2018

Carol H. Steckel Commissioner Department for Medicaid Services 275 East Main Street, 6 West A Frankfort, KY 40621

Dear Ms. Steckel:

The Commonwealth of Kentucky submitted its Substance Use Disorder (SUD) Implementation Protocol, including the Health Information Technology (IT) plan, as required by special term and conditions (STC) of the state's section 1115 Kentucky Helping to Engage and Achieve Long Term Health (HEALTH) demonstration (Project No. 11-W-00306/4). The Centers for Medicare & Medicaid Services (CMS) has reviewed the SUD Implementation Protocol and the SUD Health IT plan, and determined that it is consistent with the requirements outlined in the STCs; therefore, with this letter, the state may now begin receiving Federal Financial Participation (FFP) for Kentucky Medicaid recipients residing in the Institutions for Mental Disease (IMD) under the terms of this demonstration.

If you have any questions, please contact your project officer, Ms. Valisha Andrus, at <u>Valisha.Andrus@cms.hhs.gov</u>. We appreciate your cooperation throughout the review process.

Sincerely,

/s/

Andrea J. Casart Director Division of Medicaid Expansion Demonstrations

Enclosure

cc: Shantrina Roberts, Associate Regional Administrator, CMS Atlanta Regional Office

TUCKY	HEALTH
KE	

<u>Commonwealth of Kentucky</u> Section 1115 Substance Use Disorder (SUD) Demonstration <u>Implementation Plan</u>

Date: 10-05-18

Overview

among the Substance Use Disorder (SUD) population the number of patients who have one of the common co-morbidities associated (CDC) identified 220 counties in the United States that are most susceptible for Human Immunodeficiency Virus (HIV) outbreak, of with SUD are much greater than patients without an SUD. For example, the state has seen a rapid increase (nearly 115%) in cases of Neonatal Abstinence Syndrome (NAS).² Of those cases, Medicaid accounted for over 80%. In 2016 the Center for Disease Control Kentuckians due fatal drug overdoses. Over the past 5 years Kentucky has seen a 38% increase in overdose deaths. Historically The Commonwealth of Kentucky is facing a substance use crisis of epic proportions. ¹ In 2016, the commonwealth lost 1,404 the 220 counties 54 reside in the Commonwealth of Kentucky. Kentucky has created multiple initiatives to combat the SUD crisis and increase awareness. Below are a number of programs that have either been implemented or are under development:

- In 2012, Kentucky passed sweeping legislation that has become a national model. This statute required; the use of Prescription Drug Monitoring Program (PDMP) for all prescribers of controlled substances, regulated pain clinics by requiring them to be physician or hospital owned, and fostered increased cooperation among the PDMP, Kentucky licensure boards and law enforcement. 0
 - In 2015, Kentucky passed several harm reduction measures including; Syringe Exchange, Naloxone Distribution and the Good Samaritan Law. 0
- buprenorphine prescribing guidelines to help improve the effectiveness of medication assisted treatment with In 2015, the Kentucky Board of Medical Licensure (KBML) promulgated a regulation containing buprenorphine. 0

¹Slide 5 SUD DMS Provider Forums 2017 (using 2011-2016 data)

² Produced by the Kentucky Injury Prevention and Research Center, May 2016. Kentucky Inpatient Hospitalization Claims Files, Frankfort, KY, [2000-2015]; Cabinet for Health and Family Services, Office of Health Policy. Data for 2010-2015 are provisional; therefore these results are subject to change.

5
KEN

- In 2017 House Bill 333 Introduced as the professional standard of a 3-day prescribing limit on Schedule II controlled substances for acute pain. 0
 - Kentucky Opioid Response Effort (KORE) Initiatives:
- as part of an assertive, ongoing engagement effort. Individuals accepting services will have rapid access admitted to the Emergency Room as a result of drug overdose will have the option to begin treatment at treatment staff (e.g., case managers, certified providers, and licensed evaluator) will contact individuals ER Bridge Clinics – Established Bridge Clinics in three (3) major Hospital Systems, where individuals a "Bridge Clinic", which will then be able to provide Medication Assisted Treatment (MAT). Peer Support Specialists will also meet with individuals in the ED to provide support around accessing treatment and recovery services. Following discharge, Peer Support Specialists as well as other to treatment, including MAT, by being transferred to a Bridge clinic located nearby.
 - Sponsoring opioid stewardship aimed at prescriber education and reducing the dependence on opioids for pain management.
- Department for Behavioral Health Developmental and Intellectual Disabilities (DBHDID) Grant > Behavioral Expand prevention programs Sources of Strength in middle, high and post-secondary institutions.

- Health & Primary Care Integration.
 State Wide Screening referral service for substance abuse treatment Helpline.
- In 2018 Kentucky will implement -a Web based treatment locator designed for referrals from Primary Care Physicians, Emergency Room and Health Departments. 0
- Addition of Methadone coverage for SUD treatment via state plan.



<u>Section I – Milestone Completion</u>

Milestones

1. Access to Critical Levels of Care for OUD and Other SUDs

range of services at varying levels of intensity across a continuum of care since the type of treatment or level of care needed may be To improve access to Opioid Use Disorder (OUD) and SUD treatment services for Medicaid beneficiaries, it is important to offer a more or less effective depending on the individual beneficiary.

- Outpatient Services;
- Intensive Outpatient Services;
- Medication assisted treatment (medications as well as counseling and other services with sufficient provider capacity to meet needs of Medicaid beneficiaries in the state);
 - Intensive levels of care in residential and inpatient settings; and
- Medically supervised withdrawal management

Milestone Criteria	Current State	Future State	Summary of Actions Needed
Coverage of outpatient	Department for Medicaid	Will add treatment plan	Amend State Plan to
services	Services (DMS) currently	development for alcohol	include service planning
	provides a comprehensive	and/or substance abuse to the	for SUD treatment.
	array of behavioral health	array of services allowed in	Update regulations to
	services including; Screening,	State Plan. Will continue	reflect added service.
	Assessment, Crisis	providing coverage of	DMS Division of Policy
	Intervention, Partial	outpatient services through	and Operations will
	Hospitalization, Individual,	the State Plan.	oversee completion of
	Group and Family therapies,		tasks.
	Peer Support, Targeted Case		

► I
X
S L
FI
Z
Ш
X
1

W			
	Management, and residential service for SUD. DMS also provides medication assisted treatment with buprenorphine, and vivitrol. These services will continue under Kentucky's State Plan. <u>Click Here for State Plan</u> <u>Amendment</u>		 DMS Senior Behavioral Health Policy Advisor will oversee completion of tasks. Estimated completion September 12, 2019.
Coverage of intensive Int outpatient services [Int Statistic fire free or or or pressed presse	Intensive Outpatient Program (IOP) is currently a covered service through Kentucky's State Plan and is an alternative to or transition from inpatient hospitalization or partial hospitalization for mental health or substance use disorders. IOP must be provided at least three (3) hours per day and at least three (3) days per week. This service will continue under Kentucky's State Plan. Partial Hospitalization is a short-term (average of four (4) to six (6) weeks), less than 24 hour, intensive treatment program for individuals experiencing significant impairment to daily functioning due to substance	Currently Partial Hospitalization may be provided in a hospital or Community Mental Health Center (CMHC). Propose to add Behavioral Health Services Organization (BHSO) as an allowable setting to perform partial hospitalization services. Will continue to cover IOP throughout the demonstration under State Plan.	 Amend regulations adding partial hospitalization to the service array for a BHSO. DMS Senior Behavioral Health Policy Advisor will oversee completion of tasks. September 12, 2019 completion fimplementation plan.

>T	
GF	-
¥-	1
U	
54	-
	•
-	
4	
ш	
Y	
100	

	use disorders, mental health disorders or co-occurring mental health and substance use disorders. This service is designed for individuals who cannot effectively be served in community-based therapies or IOP. <u>Click Here for State Plan</u> <u>Amendment</u>		
Coverage of medication assisted treatment (medications as well as counseling and other services with sufficient provider capacity to meet needs of Medicaid beneficiaries in the state)	DMS currently covers MAT for Buprenorphine and Vivitrol.	DMS will expand MAT to cover Methadone for the treatment of Substance Use Disorders.	 DMS will amend the State Plan to include coverage of Methadone for MAT. Amend behavioral health services organization regulation to include narcotic treatment program. DMS Senior Behavioral Health Policy Advisor will oversee completion of tasks. Estimated Time Frame: September 12, 2019.
Coverage of intensive levels of care in residential and inpatient settings	DMS currently provides coverage of residential services for Substance Use Disorders (SUD) in the State Plan. Services must be provided under the medical direction of a physician and provide continuous nursing	Kentucky will perform its own certification program developing forms for on-site visits with a four-person team from Department for Medicaid Services Behavioral Health Policy Team. DMS will certify providers to the	 State Plan Amendment and Regulation changes to reflect certification levels DMS Senior Behavioral Health Policy Advisor will oversee completion of tasks.



services in which a registered	appropriate ASAM level for	On-Site certification
nurse shall be on-site during	residential services in the	forms completed by
traditional first shift hours,	current edition of The ASAM	October 15, 2018
continuously available by	criteria.	On-Site provider
phone after hours' and on-site		certification completed by
as needed in follow-up to		01/15/2019.
telephone consultation after		
hours. Residential coverage		
have two levels of treatment.		
Short term services should		
have twenty-four (24) hour		
staff and have a duration of		
less than thirty (30) days.		
Long term services should		
have twenty-four (24) hour		
staff as required by licensing		
regulations with lengths of		
stay thirty (30) to ninety (90)		
days. DMS will not pay for		
this service in a unit of more		
than 16 beds or multiple units		
operating as one unified		
facility with more than 16		
aggregated beds except for		
services furnished pursuant to		
the state plan benefit		
"inpatient psychiatric services		
for individuals under twenty-		
one (21)" (section 1905(a)(16)		
of the Act; 42 CFR 440.160)		
or pursuant to an exclusion for		
individuals age 65 or older		
who reside in institutions that		

T
CF
Ш
-I
Z
ш
X

	 Amend service definitions to include withdrawal management at appropriate levels of care within State Plan and KY regulations. DMS Senior Behavioral Health Policy Advisor will oversee completion of tasks. Completed by September 12, 2019.
	DMS will incorporate all levels of withdrawal management (Level 1 –WM Ambulatory withdrawal management without extended on-site monitoring, Level 2-WM Ambulatory withdrawal management with extended on-site monitoring, Level 3-WM Residential/inpatient withdrawal management and Level 3.2-WM Clinically managed residential withdrawal management, Level 3.7-WM medically monitored inpatient withdrawal management and Level 4- WM Medically managed intensive inpatient
are Institution for Mental Disease (IMDs) (section 1905(a) of the Act; 42 CFR 440.140.). Require BHSO to be licensed as a non-medical and non-hospital based alcohol and other drug treatment program in accordance with state licensing regulations. <u>Click Here for State Plan</u> <u>Amendment</u>	DMS currently covers medical detox in a hospital setting.
	Coverage of medically supervised withdrawal management(WM)

	Ľ
Ž	EAL
E	Ľ
EN	
¥	

2. Use of Evidence-based, SUD-specific Patient Placement Criteria

Implementation of evidence-based, SUD-specific patient placement criteria is identified as a critical milestone that states are to address as part of the demonstration. To meet this milestone, states must ensure that the following criteria are met:

- Providers assess treatment needs based on SUD-specific, multi-dimensional assessment tools, e.g., the ASAM Criteria, or other patient placement assessment tools that reflect evidence-based clinical treatment guidelines; and
- appropriate level of care, (b) interventions are appropriate for the diagnosis and level of care, and (c) there is an independent Utilization management approaches are implemented to ensure that (a) beneficiaries have access to SUD services at the process for reviewing placement in residential treatment settings. •

recovery services for individuals with an SUD through the contractual requirement with the MCO's. Below is the language utilized in Currently DMS, through Managed Care Contracts require the use of ASAM Criteria for authorization regarding Level of Care (LOC) predetermined limits of care established for these services. Continued involvement in a level of care is based on individual need determined through medical necessity criteria. DMS will continue to require ASAM Criteria for authorization of treatment and for SUD treatment. Managed Care Organizations (MCO) apply ASAM to both outpatient and residential services with no the MCO contracts to address utilization management.

approved under a prior contract must be resubmitted to ensure it meets the requirements of this Contract. ³The MCO's shall have in place mechanisms to check the consistency of application of review criteria. scope that is less than requested, must be made by a physician who has appropriate clinical expertise in information, including pertinent clinical information, and consultation with the attending physician or other health care provider as appropriate. The Medical Director and Behavioral Health Director shall Decisions to deny a service authorization request or to authorize a service in an amount, duration, or supervise the UM program and shall be accessible and available for consultation as needed. Criteria reating the Member's condition or disease. The clinical reason for the denial, in whole or in part, The written clinical criteria and protocols shall provide for mechanisms to obtain all necessary

³ Language from MCO SFY 18 Contracts



shall include a provision for expedited reviews in urgent decisions. Post-service review requests shall be Contractor justifies a need for additional information and how the extension is in the Member's interest, Necessity review process shall be completed within two (2) business days of receiving the request and specific to the Member shall be cited. Physician consultants from appropriate medical, surgical and completed within fourteen (14) days or, if the Member or the Provider requests an extension or the osychiatric specialties shall be accessible and available for consultation as needed. The Medical may extend up to an additional fourteen (14) days.

A. The MCO's shall submit its request to change any prior authorization requirement to Department for Medicaid Services (DMS) for review. B. For the processing of requests for initial and continuing authorization of services, the Contractor shall require that its subcontractors have in place written policies and procedures and have in effect a mechanism to ensure consistent application of review criteria for authorization decisions.

shall provide written confirmation of its decision within three working days of providing notification of C. In the event that a Member or Provider requests written confirmation of an approval, the Contractor a decision if the initial decision was not in writing. The written confirmation shall be written in accordance with Member Rights and Responsibilities.

D. The Contractor shall have written policies and procedures that show how the Contractor will monitor to ensure clinically appropriate overall continuity of care.

E. The Contractor shall have written policies to ensure the coordination of services:

1. Between settings of care, including appropriate discharge planning for short term and long-term hospital and institutional stays;

2. With the services the Member receives from any other MCO;

3. With the services the member receives in Fee for Service (FFS); and

4. With the services the Member receives from community and social support providers.

F. The MCO shall have written policies and procedures that explain how prior authorization data will be incorporated into the MCO's overall Quality Improvement Plan.

of care. DMS does not require the provider to utilize one specific multi-dimensional tool. In regulation, DMS defines assessment to DMS providers perform an assessment and collect other relevant information that will assist in determining the most appropriate level include gathering information and engaging in a process with the individual that enables the provider to:



- Establish the presence or absence of a mental health disorder, substance use disorder, or co-occurring disorders; 0
 - Determine the individual's readiness for change;
- Identify the individual's strengths or problem areas that may affect the treatment and recovery processes; and 0
 - Engage the individual in developing an appropriate treatment relationship;
 - Include working with the individual to develop a treatment and service plan; and Establish or rule out the existence of a clinical disorder or service need;
 - Does not include psychological or psychiatric evaluations or assessments. •

assist the provider to create a holistic, biopsychosocial assessment of the recipient that will assist the provider with development of the As part of the new waiver benefit, Kentucky will require utilization of ASAM's six dimensions of multidimensional assessment to ensure consistency in the assessment and treatment planning process for treatment of substance use disorders. The dimensions will treatment planning for any person seeking SUD services. The dimensions include acute intoxication and/or withdrawal potential; biomedical conditions and complications; emotional, behavioral or cognitive conditions and complications; readiness to change; relapse, continued use, or continued problem potential and recovery/living environment.

and ensure all providers will be trained on ASAM criteria. The estimated timeline for completion of changes in regulations related to incorporate these dimensions as part of their assessment by September 12, 2019. DMS will outline requirements within regulations counselor or clinician, a certified addiction registered nurse, a psychologist or a physician. DMS will require all SUD providers to DMS will ensure that providers are utilizing the appropriate clinician to perform the assessment which include a credentialed assessment criteria is September 12, 2019. DMS Division of Policy and Operations will oversee completion of task.

3. Use of Nationally Recognized SUD-specific Program Standards to Set Provider Qualifications for Residential Treatment Facilities

Through the new Section 1115 initiative, states will have an opportunity to receive federal financial participation (FFP) for a continuum of SUD services, including services provided to Medicaid enrollees residing in residential treatment facilities that qualify as institutions for mental diseases. To meet this milestone, states must ensure that the following criteria are met:

contracts, or other guidance) that meet the ASAM Criteria or other nationally recognized, SUD-specific program standards Implementation of residential treatment provider qualifications (in licensure requirements, policy manuals, managed care regarding the types of services, hours of clinical care and credentials of staff for residential treatment settings;

T
\mathbf{X}
114
Z
1.1
111
\checkmark

- Implementation of a state process for reviewing residential treatment providers to assure compliance with these standards; and
- Implementation of a requirement that residential treatment facilities offer MAT on-site or facilitate access off site.

Currently DMS only reimburses residential SUD treatment with providers who have less than sixteen (16) bed facilities or for recipients who are under the age of twenty-one (21) or over the age of sixty-four (64). CMHC's, BHSO's and hospitals are DMS provider types licensed through Office of Inspector General (OIG) and provide residential SUD services. These services are based on individual need and may include screening, assessment, service planning, peer support, individual, group and family outpatient therapy. DMS requires residential services be provided under the medical direction of a physician and provide continuous nursing services on site during traditional first shift hours Monday through Friday and continuously available for telephone consultation afterhours and onsite as needed. The Commonwealth of Kentucky will conduct a statewide survey to assess the current landscape of behavioral health providers. We began with a survey sent out to all Medicaid enrolled residential substance use disorder providers. One component of this survey was Based on the self-attestation Kentucky would allow for reimbursement of residential services up to 96 beds in an IMD pending certification by the State conducted certification process. DMS is internally considering payment adjustment based on residential level for the residential providers to self-attest to their level of ASAM residential care. This survey is currently underway for our residential SUD treatment providers, with an expected completion date of October 15, 2018. This will align with the DMS led certification process. of care.

In order for a SUD residential provider to be eligible for the Institution of Mental Disease (IMD) exclusion, Kentucky will require the provider to be certified to the ASAM residential levels of care which are; 3.1 Clinically Managed Low-Intensity Residential Services, 3.3 Clinically Managed Population Specific High Intensity Residential Services, 3.5 Clinically Managed High-Intensity Residential Services, 3.7 Medically Monitored Intensive Inpatient Services. Kentucky Revised Statutes (KRS) 216B.015 defines the Office of Inspector General, Division of Health Care responsible for inspecting, monitoring, licensing and certifying all health care facilities. ASAM certified will then be able to receive the IMD exclusion for up to 192 beds for short-term residential treatment. Short-term This includes acute care hospitals, which DMS designate as Medically Managed Intensive Inpatient Services. Kentucky feels the licensure requirement is sufficient and does not require this level of care to be certified. The SUD residential providers that are residential treatment is defined as a statewide average length of stay of thirty (30) days. Kentucky will perform its own certification program of residential levels: 3.1 Clinically Managed Low-Intensity Residential Services, 3.3 Clinically Managed Population Specific High Intensity Residential Services, 3.5 Clinically Managed High-Intensity Residential person team from Department for Medicaid Services Behavioral Health Policy team. Beginning October 15, 2018 this team will Services, and 3.7 Medically Monitored Intensive Inpatient Services. Kentucky is developing forms for on-site visits with a four-

Y
Uq
— Ш
Z
1
111
-

begin to conduct onsite visits of all Medicaid enrolled SUD residential providers to review settings, staff requirements, co-occurring completed by January 15, 2019. Moving forward DMS will continue to explore engaging with ASAM to participate in the pilot for capacity, and programming utilizing state created forms. Certification of all Medicaid enrolled residential SUD providers will be level of care certification. DMS currently offers all the service components of MAT within the State Plan. Methadone is currently payable for pain not for SUD providers are providing MAT on-site or facilitating access off site, by conducting a provider survey. The offsite facilitation of MAT treatment. DMS is adding the coverage of Methadone to our State Plan services for the treatment of SUD and will ensure residential medication as a part of their plan of care to receive the medication services outside of the residential provider. As part of the care for residential providers that do not provide medication as part of their treatment continuum will allow individuals who opt for coordination in a residential setting, the care coordinator will assist in the logistics of locating, scheduling and transporting an individual for their offsite medication services.


recovery that include residential, outpatient and medication-assisted treatment (MAT) services. This legislation requires enhanced and streamline licensure requirements for SUD treatment providers as well as create statewide standards and outcome measures to ensure Kentucky has legislation to require the Cabinet of Health and Family Services (CHFS) to develop enhanced licensure and quality standards. These will be based on nationally recognized and evidence-based standards for substance use disorder treatment and quality. DMS Division of Policy and Operations Senior Behavior Health Policy Advisor will oversee completion. Estimated for completion by September 12, 2019.



4. Sufficient Provider Capacity at Critical Levels of Care including for Medication Assisted Treatment for OUD

management, throughout the state. This assessment should help to identify gaps in availability of services for beneficiaries in the To meet this milestone, states must complete an assessment of the availability of providers enrolled in Medicaid and accepting new patients in the critical levels of care listed in Milestone 1. This assessment must determine availability of treatment for Medicaid beneficiaries in each of these levels of care, as well as availability of MAT and medically supervised withdrawal critical levels of care.





treatment (MAT) service capability. Through onsite visits we will verify MAT is offered on-site or facilitated offsite. Completion of DMS to develop and conduct a survey for Medicaid and Non-Medicaid providers to determine what services they provide related to SUD levels of care and potential for Medicaid enrollment. As part of the survey, Kentucky will be looking at medication assisted provider survey will be within twelve (12) months of Implementation Plan approval. DMS Division of Policy and Operations is responsible for completion of task.



Milestone Criteria	Current State	Future State	Summary of Actions Needed
Completion of assessment		Kentucky Medicaid is conducting a	
ot tile availautitty of providers enrolled in		state where survey of the attribution in the providers that currently offer	Develop preletred
Medicaid and accepting new		outpatient. Intensive Outpatient	in alignment with
patients in the following		services, MAT and Residential	Pharmacy
critical levels of care		services. With pending changes to	prescribing program.
throughout the state (or at		licensure requirements for SUD	
least in participating regions		treatment and recovery providers,	DSM Senior
of the state) including those		Kentucky Medicaid will create a	Behavioral Health
that offer MAT:		Preferred prescriber program that	Policy Advisor and
		incorporates DMS Pharmacy	DMS Pharmacy
Outpatient Services;		prescribing program. Participation	Director will oversee
		in the preferred provider program	completion of task.
Intensive Outpatient		will reduce the administrative	4
Services;		burden on the provider. The	Completion by
		following are the requirements for	September 12, 2019
Medication Assisted		participation:	
Treatment (medications as		Providing treatment under	
well as counseling and other		the license of a	
services);		buprenorphine waivered	
		practitioner and co-located	
Intensive Care in		credentialed addiction	
Residential and Inpatient		treatment practitioners,	
Settings;		Can distribute	
		buprenorphine products	
Medically Supervised		during induction	
Withdrawal Management.		Provide prescriptions for	
		buprenorphine products	

T
-
-
- m
A
and and

Provide psychosocial treatment for opioid use	assessment of psychosocial needs, individual and/or	group counseling, linkage and referral to community	based services and support	systems, care coordination of on-site and off-site	treatment services,	medical/prescription	monitoring.
•							

5. Implementation of Comprehensive Treatment and Prevention Strategies to Address Opioid Abuse and OUD

To meet this milestone, states must ensure that the following criteria are met:

- Implementation of opioid prescribing guidelines along with other interventions to prevent prescription drug abuse; •
- Expanded coverage of and access to naloxone for overdose reversal; and
- Implementation of strategies to increase utilization and improve functionality of prescription drug monitoring programs. •

Summary of Actions Needed	Develop program draft including revised clinical criteria and prior authorization forms -DMS Pharmacy Director is responsible for completion of this task
Future State S	
Current State	Prescribers are required to;Revised buprenorphineobtain a report on beneficiaries from the prescription drug monitoring program (PDMP), obtain drug screens and encourage the patient's active participationRevised buprenorphine criteria to increase response access and treatment.Prescription drug monitoring program (PDMP), obtain drug patient's active participationRevised buprenorphine criteria to increase response access and treatment.
Milestone Criteria	Implementation of opioid prescribing guidelines along with other interventions to prevent opioid abuse

T
¥ .
$\mathbf{O} \triangleleft$
- 111
-
7
Y

in a behavioral modification program.		-Expected on or before 11/1/18
DMS has implemented a 3 day supply limitation for controlled substances. (See statute link below) Click Here for KRS 218A.205	The Department for Medicaid Services (DMS) will align the Prior Authorization requirements (PA) for prescribing or dispensing buprenorphine –mono-product or buprenorphine combined with naloxone, with the professional standards from the KBML. (See regulation link below) Click Here for 201 KAR 9:270	Develop two (2) prior authorization forms. The first form aligning with KBML standards, the second form for the buprenorphine program. -DMS Pharmacy Director is responsible for completion of this task - Following alignment of requirements there will be a 90 day provider notice and education period before changes can Go-Live. Expected on or before 11/1/18.
	Opioid Utilization Program that will include revised criteria to apply varying utilization controls to long acting opiates and short acting opiates; plus, the implementation of a Morphine Milligram Equivalent (MME) dosing limitations program, including treatment plan agreements and opiate PA requirements.	In-Progress -DMS Pharmacy Director is responsible for completion of this task -Approved by KY P&T Committee on 5/01/18; Go- Live 09/04/18



A brief summary of the utilization controls being reviewed include: limitations on Short Acting (SA) opioids for the treatment of acute pain, limitations on the	treatment of chronic, non- cancer pain in non-hospice patients, other class limitations such as age limits, daily dose limits, limits on cough and cold opioid containing products, limits on codeine and tramadol products, and required review of overlapping claims for opioids and benzodiazepines.	The MME dosing limitations involve a claim by claim analysis of current member utilization of both Long Acting (LA) and SA opioids. Once complete we will have a better understanding of how members may be utilizing multiple prescriptions to achieve higher cumulative MME and their per day dosing. A simplified conversion factor of 4



be used to resolve the IT	systems limitations	surrounding sliding scale as	recommended by CMS, until	there is a new software	release. Analysis will reveal	the most common products	contributing to the MME per	day over 180 and over 300	both for FFS and the MCO	populations. The program will	allow exceptions for certain	disease states such as cancer,	sickle cell, and hospice.	Additional considerations will	apply for others like Long	Term Care (LTC), acute	surgical procedures, and	Narcotic Treatment Program	(NTP). We will establish	MME thresholds for SA, LA,	and combo use of opioids.	And employ a step down	methodology to reduce overall	MME.	Prior Authorizations will be	revised to allow for new	initial limits of opioids	without PA up to a certain	threshold MME (eg	90MME/day), while higher	quantities require post limit
																							-								

N
() 1
-
7

MMIE threshold (e.g., 200MME/day) Post imit PA approvals will be limited in duration for acute pain treatment (30 days) but one year for chronic pain en erginic pain on treasessment intervied patient reasessment intervied patient sectors intervied patient sectors intervied patient sectors intervied patient sectors issisted Treatment (MATI)Interse treatment (MATI) intervied patient sectors issisted Treatment (MATI) dispensers. families and spensers. families and spensers. families and tisk to primary provider sone a collaborative care agreement a treatment. Resources and perscription is required, under a collaborative care agreement a dreatment. Resources and prescription is required, under a collaborative care agreement a dreatment. Resources and perscription is required, under a collaborative care agreement a dreatment. Resources and perscription is required, under a collaborative care agreement a dreatment. Resources and perscription is required, under a collaborative care agreement a dreatment or a d			PA, with an overall max	
All Kentucky Health PlansmunovarticationAll Kentucky Health PlansAll Kentucky Health PlansAll Kentucky Health PlansIncrease access to MedicationAll Kentucky Health PlansIncrease access to MedicationNasal Spray and syringesIncrease access to Medicationauthorization. Although aIncrease access to mercigency roomauthorization. Although and treatment. Resources andIncreased.As part Kentucky's OpioidResponse Effort, Narcan kits(set of 2 doses) are distributedIn the highest-risk regions ofthe Department for PublicHealth's mobile pharmacieswho enter into an agreementIncreased.			MME threshold (e.g 200MME/day). Post limit PA approvals will be limited in duration for acute pain treatment (30 days) but one year for chronic pain care. This will include some required patient reassessment	
All Kentucky Health PlansIncrease access to MedicationAll Kentucky Health Planscurrently cover naloxonecurrently cover naloxoneAssisted Treatment (MAT)Nasal Spray and syringesmithout a co-pay or priorwithout a co-pay or priorauthorization. Although aprescription. Although aproviders to connect serviceswithout a co-pay or priordischarge for overdose or highprescription is required, underand treatment. Resources anda collaborative care agreementand treatment. Resources andpharmacists throughout theconnectivity to those forcommonwealth are permittedbeneficiaries in treatment orwithin a high risk populationswithin a high risk populationsare fororders for naloxone products.As part Kentucky's Opioidwithin a high risk populationsResponse Effort, Narcan kitswill also be increased.fue Of 2 doses) are distributedin the highest-risk regions ofthe Department for PublicHealth's mobile pharmacy aswell as individual pharmacieswho enter into an agreement			exceptions for those actively battling cancer.	
SubsectionAlthough a without a co-pay or prior authorization. Although a authorization is required, under authorization is required, under a collaborative care agreement pharmacists throughout the commonwealth are permitted to initiate protocol driven orders for naloxone products.providers to connect services between emergency room discharge for overdose or high risk to primary provider care and treatment. Resources and connectivity to those for beneficiaries in treatment or within a high risk populations within a high risk populations within a high risk populations (set of 2 doses) are distributed in the highest-risk regions of the Department for Public 		All Kentucky Health Plans currently cover naloyone	Increase access to Medication Assisted Treatment (MAT)	This effort to educate; heneficiaries prescribers
without a co-pay or priorbetween emergency roomauthorization. Although abetween emergency roomauthorization. Although aprescription is required, underprescription is required, undera collaborative care agreementa collaborative care agreementpharmacists throughout thepharmacists throughout theconnectivity to those forpharmacists throughout thebeneficiaries in treatment orpharmacists for naloxone products.within a high risk populationsare forAs part Kentucky's OpioidResponse Effort, Narcan kitswill also be increased.fin the highest-risk regions ofthe Commonwealth throughthe Department for PublicHealth's mobile pharmacieswell as individual pharmacieswho enter into an agreement		Nasal Spray and syringes	providers to connect services	dispensers, families and
authorization. Although a prescription is required, under a collaborative care agreement pharmacists throughout the Commonwealth are permitted to initiate protocol driven orders for naloxone products. As part Kentucky's Opioid Response Effort, Narcan kits (set of 2 doses) are distributed in the highest-risk regions of the Department for Public Health's mobile pharmacy as well as individual pharmacies who enter into an agreement		without a co-pay or prior	between emergency room	schools will be on-going.
prescription is required, under a collaborative care agreement pharmacists throughout the Commonwealth are permitted to initiate protocol driven orders for naloxone products. As part Kentucky's Opioid Response Effort, Narcan kits (set of 2 doses) are distributed in the highest-risk regions of the Commonwealth through the Department for Public Health's mobile pharmacy as well as individual pharmacies who enter into an agreement		authorization. Although a	discharge for overdose or high	
ge of, and pharmacists throughout the Commonwealth are permitted to initiate protocol driven orders for naloxone products. As part Kentucky's Opioid Response Effort, Narcan kits (set of 2 doses) are distributed in the highest-risk regions of the Commonwealth through the Department for Public Health's mobile pharmacy as well as individual pharmacies who enter into an agreement		prescription is required, under	risk to primary provider care	
ge of, and to initiate protocol driven orders for naloxone products. As part Kentucky's Opioid Response Effort, Narcan kits (set of 2 doses) are distributed in the highest-risk regions of the Commonwealth through the Department for Public Health's mobile pharmacy as well as individual pharmacies who enter into an agreement		a contabolative care agreement	and deamicant. Nessurices and connectivity to those for	
ge of, and to initiate protocol driven ne for orders for naloxone products. As part Kentucky's Opioid Response Effort, Narcan kits (set of 2 doses) are distributed in the highest-risk regions of the Commonwealth through the Department for Public Health's mobile pharmacy as well as individual pharmacies who enter into an agreement		Commonwealth are permitted	beneficiaries in treatment or	
ae for orders for naloxone products. As part Kentucky's Opioid Response Effort, Narcan kits (set of 2 doses) are distributed in the highest-risk regions of the Commonwealth through the Department for Public Health's mobile pharmacy as well as individual pharmacies who enter into an agreement	ed coverage of, and	to initiate protocol driven	within a high risk populations	
As part Kentucky's Opioid Response Effort, Narcan kits (set of 2 doses) are distributed in the highest-risk regions of the Commonwealth through the Department for Public Health's mobile pharmacy as well as individual pharmacies who enter into an agreement	o, naloxone for e reversal	orders for naloxone products.	will also be increased.	
Response Effort, Narcan kits (set of 2 doses) are distributed in the highest-risk regions of the Commonwealth through the Department for Public Health's mobile pharmacy as well as individual pharmacies who enter into an agreement		As part Kentucky's Opioid		
(set of 2 doses) are distributed in the highest-risk regions of the Commonwealth through the Department for Public Health's mobile pharmacy as well as individual pharmacies who enter into an agreement		Response Effort, Narcan kits		
in the highest-risk regions of the Commonwealth through the Department for Public Health's mobile pharmacy as well as individual pharmacies who enter into an agreement		(set of 2 doses) are distributed		
the Commonwealth through the Department for Public Health's mobile pharmacy as well as individual pharmacies who enter into an agreement		in the highest-risk regions of		
the Department for Public Health's mobile pharmacy as well as individual pharmacies who enter into an agreement		the Commonwealth through		
Health's mobile pharmacy as well as individual pharmacies who enter into an agreement		the Department for Public		
well as individual pharmacies who enter into an agreement		Health's mobile pharmacy as		
		well as individual pharmacies		



with KPhA to dispense KORE-funded kits.	KPhA is also helping to establish partnerships between community pharmacies and residential treatment programs to ensure individuals have free take-home Narcan upon discharge. A pharmacist comes to the treatment centers to provide the kits as well as training on their use.	People Advocating Recovery (PAR) is distributing Narcan kits in community settings targeting eastern Kentucky, other underserved counties, and Oxford Houses. In addition to training on use, education is provided on signs and symptoms, stigma, and Good Samaritan law.	In addition 1,000 Narcan kits are being distributed across four Emergency Departments (UK, UL, St. Elizabeth, and St. Claire) to individuals having experienced or at risk for opioid overdose.

NT.
CE
U
ΞШ
LI
Z
11
\checkmark
1

		1
		-

ſ

6. Improved Care Coordination and Transitions between Levels of Care

To meet this milestone, states must implement policies to ensure residential and inpatient facilities link beneficiaries, especially those with OUD, with community-based services and supports following stays in these facilities.

Summary of Actions Needed	Amend State Plan to include	care coordination within the	SUD residential treatment	definition outlining the duties	of care coordination.	Amend State Regulations to	include care coordination	duties to the SUD residential	treatment definition.		DMS Senior Behavioral	Health Policy Advisor will	oversee completion of	tasks.	Comulated by Sentember	12 2019	12, 2017.
Future State	Kentucky Medicaid will	implement care coordination	services for all individuals	within residential treatment to	ensure services are	coordinated for co-occurring	conditions as well as link the	recipient to appropriate	community services by	facilitating medical and	behavioral health follow-ups	and linking to appropriate	level of substance use	treatment within the	continuum in order to provide	ongoing support for	recipients.
Current State	Kentucky currently offers	targeted case management for	individuals with a SUD and	for individuals with SUD and	a chronic/complex physical	health issue. This level of	case management is	individuals with a moderate to	severe SUD.								
Milestone Criteria	Additional policies to ensure	coordination of care for co-	occurring physical and mental	health conditions													



DMS is in the early stages of a learning opportunity with other states related to integration of primary and behavioral health care. This learning lab will assist Kentucky with development of a strategic plan to implement policy for integration of physical and behavioral disorder, criminal justice, children and youth with social-emotional disturbance, children in state custody who may have juvenile health. Kentucky's vision is to improve outcomes and reduce cost for; adults with serious mental illness and/or substance use justice involvement.

Through the Learning Lab opportunity Kentucky intends to improve linkages among health, behavioral health and criminal justice data.

<u>Section II – Implementation Administration</u>

Please provide the contact information for the state's point of contact for the Implementation plan.

Name and Title: Ann Hollen, Senior Behavior Health Policy Advisor Telephone Number: (502) 564-6890 Email Address: <u>ann.hollen@ky.gov</u>

Section III – Relevant Documents

Please provide any additional documentation or information that the state deems relevant to successful execution of the implementation plan.



Attachment A – Template for SUD Health Information Technology (IT) Plan

Section I.

Monitoring Programs (PDMP), in the SMD #17-003, states with approved Section 1115 SUD demonstrations are generally required to As a component of Milestone 5, Implementation of Strategies to Increase Utilization and Improve Functionality of Prescription Drug submit an SUD Health IT Plan as described in the STCs for these demonstrations within 90 days of demonstration approval

The SUD Health IT Plan will be a section within the state's SUD Implementation Plan Protocol and, as such, the state may not claim FFP for services provided in IMDs until this Plan has been approved by CMS.

In completing this plan, the following resources are available to the state:

- a. Health IT.Gov in "Section 4: Opioid Epidemic and Health IT."⁴
- Interoperability" and, specifically, the "1115 Health IT Toolkit" for health IT considerations in conducting an assessment and CMS 1115 Health IT resources available on "Medicaid Program Alignment with State Systems to Advance HIT, HIE and developing their Health IT Plans.⁵ þ.

As the state develops its SUD Health IT Plan, it may also request technical assistance to conduct an assessment and develop its plan to ensure it has the specific health IT infrastructure with regards to the state's PDMP plan and, more generally, to meet the goals of the demonstration. Contacts for technical assistance can be found in the guidance documents.

In the event that the state believes it has already made sufficient progress with regards to the health IT programmatic goals described PDMPs, and master patient index and identity management), it must provide an assurance to that effect via the assessment and plan in the STCs (i.e. PDMP functionalities, PDMP query capabilities, supporting prescribing clinicians with using and checking the below (see Table 1, "Current State").

⁴ Available at https://www.healthit.gov/playbook/opioid-epidemic-and-health-it.

⁵ Available at https://www.medicaid.gov/medicaid/data-and-systems/hie/index.html.

ſ

	>	T
	6	-
	U	4
		ш
		T
	2	
-	1.1	
	Y	

			completion of each	
			action item	
Prescription Drug Monite	Prescription Drug Monitoring Program (PDMP) Functionalities	nctionalities		
Enhanced interstate data	1.1 The Kentucky PDMP	1.1 CHFS plans to	1.1 Onboard additional	1.1 New States will
sharing in order to better	(KASPER) is housed in	enhance KASPER to	interstate data sharing	be added at a
track patient specific	the Cabinet for Health	support more efficient	states. Responsibility:	rate of
prescription data	and Family Services	onboarding of additional	KASPER Integration	approximately 1
	(CHFS) Office of	states.	Project Manager	per month
	Inspector General (OIG).	1.2 CHFS is beginning	(OATS). Target	beginning in
	KASPER is currently able	to work with the Bureau	completion: July 2021.	July, 2018.
	to share data with 12	of Justice Assistance and		Monthly
	states including our six	PDMP Training and	1.2 Develop data	meetings are
	border states that have	Technical Assistance	analytic functionality to	held. Currently
		Center to investigate the	allow	we are sharing
		use of data analytics to	nrescriber/nharmacist	data with 12
	1 2 Interstate data is	inform end users of high	lisers to make a more	states. The plan
		probability patient data	informed desiring on	1s to be
		matching states to select		connected to the
	and pnarmacist PDMP	when performing an	other states from which	remaining states
	users. KASPER users	interstate request	to request data based on	and D.C. by
	currently have no tools or		their practice location	July of 2021.
	analytics available to		and patient demographic	1.2 This "Informed
	assist them with		information.	Data Sharing" is
	identifying other state		Responsibility:	to be completed
	PDMPs for which a data		KASPER Project	by April of
	request may be		Manager.	2020. The plan
	appropriate for a specific		Target completion:	begins with
	patient (informed data		April 2020.	KASPER data
	sharing.)		4	only, but will
)			spread to the
				regional and
				national level
				after proper

KENTUCKY HEALTH	
Y	

				analysis and
				testing.
				Monthly
				meetings will be
				held.
Enhanced "ease of use"	KASPER provides real-	1.1 The KASPER code	1.1 Develop a new	1.1.1 User
for prescribers and other	time access to Schedule II	was developed in	modular KASPER	management
state and federal	through V controlled	2005, and is in need	system designed to	module, 4/2019.
stakeholders	substance prescription	of modernization.	provide improved ease	
	data for authorized health	CHFS is planning	of use and operational	1.1.2 PDMP System
	care providers, state and	development of a	efficiency. The new	Application Module,
	federal law enforcement	new KASPER	system modules will	12/2019
	officers and prosecutors.	system using a	include	
	the Kentucky Medicaid	modular design.	1.1.1 User management	1.1.3 PDMP Sharing
	program and other	Included in the	module,	Module, 9/2020.
	stakeholders It allows	modular design will	1.1.2 PDMP System	
	$\mathbf{f}_{-} = 1_{-1} - 1_{-2} - 1_$		Application Module,	Weekly Meetings
	for delegates to request	be integrating with	1.1.3 PDMP Sharing	will be held thru-out
	reports on behalt of	Electronic Health	Module.	the entire project.
	prescribers and	Record (EHR)	Responsibility:	
	dispensers, and allows for	system's and the	KASPER Project	1.2 This drill down
	institutional accounts to	statewide Kentucky	Manager	ontion is exnected
	simplify access for	Health Information	Target completion:	by early 2020. This
	providers in hospitals and	Exchange (KHIE).	September 2020.	phase 2 option will
	long term care facilities.		1	have monthly
	The available controlled	1.2 To increase	1.2 Implement phase 2	meetings between
	substance information	KASPER	of the enhanced	KASPER IT team
	includes opioid morphine	effectiveness, the	KASPER Prescriber	and OIG.
	milligram equivalent	modernization	Report Card.	
	(MME) information,	project will include	Responsibility:	
	basic Prescriber Report	development of an	KASPER Project	
	Card data, and the ability	enhanced Prescriber	Manager.	
	to review the prescriber	Report Card that will		

∑ ⊥	
D L E A	
Z	
Y	

	controlled substance	include patient level	Target: completion date:	
	prescribing history to	data allowing	4/2020.	
	detect errors or fraud.	prescribers easier		
		identification of at-		
		risk patients.		
	There is currently limited	Planned projects to	1.1 Drug toxicity screen	1.1 This interface is
	connectivity between	integrate KASPER with	results are being	nearly complete.
	KASPER and the	KHIE include the	reported by the EDs to	Will be ready by
	statewide health	following:	KHIE. The technical	12/2018.
	information exchange,		interface between	Weekly
	KHIE.	1.1 Prescriber and	KASPER and KHIE to	meetings are
		pharmacist users can	obtain information	currently held.
		request medical	regarding the presence	
		information based on a	of those results is under	1.2 This second
		suspected drug overdose	development.	phase of KASPER
		in an Emergency	Responsibility:	to KHIE integration
Enhanced connectivity		Department (ED).	KASPER Project	will begin in 2019.
between the state's			Manager.	Monthly meetings
PDMP and any statewide,		1.2 Integration with	Target completion:	will be held. Should
regional or local health		KHIE, so prescriber and	12/2018	be completed by
iniormation exchange		pharmacist KHIE users		12/2020.
		will be able to access	1.2 Develop and	
		KASPER patient data	implement technology	
		via KHIE without	to allow integrated data	
		leaving the KHIE	requests and responses	
		process workflow.	between KASPER and	
			KHIE.	
			Responsibility:	
			KASPER Project	
			Manager.	
			Target completion:	
			12/2020.	

 ENTUCKY	HEALTH	
Y		

Enhanced identification of long-term opioid use directly correlated to clinician prescribing patterns ⁶ (see also "Use of PDMP" #2 below)	1. KASPER currently identifies and flags patients who are receiving a current daily morphine milligram equivalent dose level of 100 or more. This includes a warning that these patients may be at a higher risk of drug overdose, and that increased clinical vigilance may be appropriate.	 1.1 KASPER reports are going to be updated to include warning flags for overlapping opioid prescriptions and overlapping opioid and benzodiazepine prescriptions. 1.2 OIG will utilize an epidemiologist to study the correlation between initial opioid use and ongoing use and abuse. 	 1.1 Modify KASPER reports to reflect overlapping controlled substance prescriptions. Responsibility: RASPER Project Manager. Target completion: 12/2019. 1.2 Study correlations between initial opioid use and patient misuse and abuse patterns, as well as potentially problematic controlled substance prescribing practices. Responsibility: OIG Epidemiologist. Target completion: ongoing. 	 1.1 This modification will take BA and Development work. Weekly meetings will be held. 12/2019. 1.2 This is an ongoing study that the Epidemiologist will lead.
Current and Future PDMP	P Query Capabilities)	
Facilitate the state's ability to properly match patients receiving opioid prescriptions with patients in the PDMP (i.e.	, ,	1.1 In March 2017 CHFS implemented a new KASPER Data Collection	1.1 Continue KASPER data quality improvement efforts. This is needed to ensure	1.1 This includes Business Analysts and Resource Management Analysts. This is an

⁶ Shah A, Hayes CJ, Martin BC. Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use — United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66:265–269. DOI: http://dx.doi.org/10.15585/mmwr.mm6610a1.

KENTUCKY				
the state's master patient index (MPI) strategy with regard to PDMP query)	substance prescription records to patients.	System. Via this system, CHFS is implementing new data reporting edits that are helping to improve the quality of data collected. The improved data quality results in increased probability of accurate patient data matching. 1.2 CHFS is planning to implement an Enterprise Data Warehouse (EDW) that will house KASPER data.	and improve data quality. Responsibility: KASPER Project Manager and Project Administrator. Target completion: ongoing. 1.2 Coordinate KASPER patient data matching processes and analytics to be consistent and support a Master Patient Indexing (MPI) within the EDW. Responsibility: KASPER Project Manager. Target completion: 6/2020.	ongoing, daily happening. 1.2 This will be done in conjunction with the Data Analytics group within the Commonwealth. Weekly meetings will be held. Target completion of 6/2020.
Use of PDMP – Supportir	Jse of PDMP – Supporting Clinicians with Changing Office Workflows / Business Processes	g Office Workflows / Busin	ness Processes	
Develop enhanced	The KASPER system is	Integrate with additional FHP and wharmary	1.1 To support additional	1.1 This process
business processes to	with a major pharmacy	systems using solutions	KASPER/EHR	the KASPER
better support clinicians	chain, and CHFS has	that present KASPER	integration and	Modernization
in accessing the PDMP nrior to nrescribing an	received requests from additional health systems	data directly in the physician	KASPER/KHIE integration OATS is	project. Weekly meetings will he
opioid or other controlled	to integrate with their	workflow. Capitalize on	conducting capacity	

KENTUCKY				
substance to address the issues which follow	EHR systems. The existing pharmacy integration allows the pharmacists to access KASPER data in one simple step without leaving their pharmacy management system workflow.	the integration work done by EHR/Pharmacy system vendors in other states.	planning reviews to ensure sufficient resources to support new integration projects. CHFS is supporting federal efforts to develop an API/Web service for PDMP/EHR integration and may also develop an in-house API/Web service to support integration projects. Responsibility: KASPER Project Manager. Target completion: 9/2020.	held during this process.
Develop enhanced supports for clinician review of the patients' history of controlled substance prescriptions provided through the PDMP—prior to the issuance of an opioid prescription	KASPER currently provides detailed prescription history and opioid MME data to health care provider users. Additional functionality is needed to improve the level of care.	 I.1 Implement the ability for all KASPER users to obtain class A misdemeanor and felony drug conviction data for the patient. I.2 Implement a patient dashboard capability to make it easier for healthcare provider KASPER users to identify overlapping 	 I.1 Implement a link to the Administrative Office of the Courts (AOC) CourtNet system to allow KASPER users to see drug conviction data for the previous five years. Responsibility: KASPER and AOC Project Managers. Target completion: 07/2018. 	 This link is currently in the testing phase and will be completed by 7/2018. Weekly meetings are currently being held. This evaluation will need to done prior to the modernization project.

T
Y
$\mathbf{O} \triangleleft$
and the second s
4
In I
100

		prescriptions, early refills, multiple provider episodes, potential drug interactions and other indicators that may indicate overdose risk, or controlled substance abuse or diversion.	 1.2 Evaluate existing patient dashboard tools and tools and capabilities, and determine whether they can be implemented into the current KASPER system or as part of the KASPER modernization project. Responsibility: OIG and OATS. Target completion: 12/2019 	
Master Patient Index / Id	' Identity Management			
Enhance the master patient index (or master data management service, etc.) in support of SUD care delivery.	While KASPER and KHIE are not currently integrated, KHIE has a defined algorithm MPI that provides match, merge and search capability.	1.1 As noted above, a KASPER/KHIE integration project is in the planning stage. As part of this project KHIE will utilize the enterprise MPI solution for querying KASPER.	 1.1 Procurement of a new KHIE vendor solution was just completed. The KASPER/KHIE integration project will be undertaken after implementation of the new KHIE system. Responsibility: KASPER and KHIE Project Managers. Target completion: 11/2019. 	1.1 This MPI will be part of the KHIE system. This will require weekly meetings to properly identify the appropriate matching parameters.
Overall Objective for Enhancing PDM		P Functionality & Interoperability		

2
T
111
7
100 M

	1.1 KASPER currently	1.1 Phase 2 of the	1.1 Implement phase 2:	1.1 This drill down
Leverage the above	includes a Prescriber	Prescriber Report Card	the enhanced KASPER	option is expected
functionalities /	Report Card that provides	will include patient level	Prescriber Report Card.	by early 2020. This
capabilities / supports (in	aggregated controlled	data allowing	Responsibility:	phase 2 option will
concert with any other	substance prescribing data	prescribers easier	KASPER Project	have monthly
state health IT, TA or	and allows prescribers to	identification of at-risk	Manager.	meetings between
workflow effort) to	compare their controlled	patients (drill down	Target: completion date:	KASPER IT team
implement effective	substance prescribing	options) These	4/2020.	and OIG.
controls to minimize the	with all Kentucky	Prescriber Report Cards		
risk of inappropriate	prescribers and with	are available to the		
opioid overprescribing	prescribers in their	Kentucky prescriber		
and to ensure that	specialty area.	licensure boards to assist		
Medicaid does not		with reviewing for		
inappropriately pay for		inappropriate or illegal		
opioids		controlled substance		
		prescribing.		

The Commonwealth of Kentucky has assessed the current infrastructure/"ecosystem" that will be necessary to achieve the goals of the demonstration. The necessary changes have been identified and captured in the Kentucky HEALTH High Level Requirements (HLR) document which will be used to help determine cost and timeline as well as to monitor the overall status throughout development and implementation.

includes behavioral health data. It will become more tightly integrated and aligned as the Kentucky HEALTH demonstration project We have reviewed our last submission of the State Medicaid Health IT Plan (SMHP), Health Information Technology Plan to verify that SUD is aligned with the plan, it is. This has been addressed in the plan with integration to eKASPER and KHIE which also moves forward.

As applicable the Commonwealth of Kentucky will advance the standards referenced in the ISA and 45 CFR Subpart B, and the Manage Care Contractor (MCO) contracts will be updated to comply with the requirements.



<u>Attachment A, Section II – Implementation Administration</u>

Please provide the contact information for the state's point of contact for the SUD Health IT Plan.

Name and Title: David Vick/KASPER Program Manager Telephone Number: 502.564.0105 x2479 Email Address: <u>david.vick@ky.gov</u>

<u>Attachment A, Section III – Relevant Documents</u>

Please provide any additional documentation or information that the state deems relevant to successful execution of the implementation plan.